What is B. Riley’s Estimate for SNDX Q3 Earnings?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – B. Riley issued their Q3 2025 earnings estimates for shares of Syndax Pharmaceuticals in a research report issued on Wednesday, August 6th. B. Riley analyst M. Mamtani expects that the company will earn ($0.68) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Syndax Pharmaceuticals’ Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.99) EPS, FY2026 earnings at ($1.16) EPS and FY2027 earnings at $0.12 EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.18. The business had revenue of $37.96 million during the quarter, compared to analysts’ expectations of $26.64 million. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The firm’s quarterly revenue was up 984.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.80) EPS.

A number of other equities analysts have also recently issued reports on SNDX. BTIG Research upped their price objective on shares of Syndax Pharmaceuticals from $43.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday. UBS Group lowered their price objective on shares of Syndax Pharmaceuticals from $37.00 to $35.00 and set a “buy” rating for the company in a research report on Tuesday, July 15th. Citigroup upped their price target on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the company a “buy” rating in a research report on Tuesday. Guggenheim restated a “buy” rating and issued a $32.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Wall Street Zen upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $36.91.

Syndax Pharmaceuticals Price Performance

SNDX stock opened at $12.48 on Friday. The company has a 50 day simple moving average of $10.08 and a 200 day simple moving average of $11.91. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -3.21 and a beta of 0.74. Syndax Pharmaceuticals has a 1 year low of $8.58 and a 1 year high of $22.50. The company has a debt-to-equity ratio of 2.06, a current ratio of 4.71 and a quick ratio of 5.75.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of institutional investors have recently modified their holdings of SNDX. Quarry LP bought a new stake in shares of Syndax Pharmaceuticals in the 1st quarter valued at $25,000. Virtus ETF Advisers LLC boosted its stake in Syndax Pharmaceuticals by 18.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock worth $70,000 after acquiring an additional 827 shares in the last quarter. Magnetar Financial LLC bought a new position in Syndax Pharmaceuticals during the first quarter worth $132,000. Optimize Financial Inc bought a new position in Syndax Pharmaceuticals during the fourth quarter worth $152,000. Finally, Lazard Asset Management LLC bought a new position in Syndax Pharmaceuticals during the fourth quarter worth $153,000.

Insider Activity at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 7,534 shares of the company’s stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $9.29, for a total value of $69,990.86. Following the sale, the chief executive officer directly owned 298,661 shares of the company’s stock, valued at approximately $2,774,560.69. This represents a 2.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 4.10% of the company’s stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).